

the saline-treated cortex was  $1.09 \pm 0.08$  pmoles/100 mg protein, whereas in the Mg-pretreated cortex,  $1.25 \pm 0.09$  pmoles/100 mg protein was detected. To demonstrate the  $Mg^{2+}$ -facilitation effect in the same animal, an additional series of experiments was undertaken in which 2.1 M  $K^+$ -induced cAMP elevation in both normal and Mg-treated hemicortices were performed in the same animal. The following values have been obtained:  $4.88 \pm 0.67$  and  $9.03 \pm 0.53$  pmoles/100 mg protein for saline and  $Mg^{2+}$ -pretreated hemicortices respectively.

According to current hypotheses, depolarizing agents, including  $K^+$ , act on the cAMP-generating system indirectly, i.e. through adenylate cyclase-linked receptors activated by adenosine and glutamate released from the cells by depolarization<sup>6-8</sup>. Our results demonstrate, however, that potassium ions are able to stimulate cAMP formation independently of their ability to evoke SD, i.e. to induce a massive depolarization of the cortical cells. This might suggest that

$K^+$  stimulates synthesis of cAMP in a direct way, besides that mediated by depolarization. The apparent facilitation effect of magnesium ions on the  $K^+$ -induced elevation of cAMP is difficult to explain as yet and remains to be elucidated by further experiments.

- 1 J. Bureš, O. Burešová and J. Krivánek, *The Mechanism and Application of Leao's Spreading Depression of Electroencephalographic Activity*, Academia, Prague 1974.
- 2 J. Krivánek, *J. Neurochem.* 26, 413 (1976).
- 3 J. Krivánek, *Brain Res.* 120, 493 (1977).
- 4 J. Krivánek, *Neuroscience* 3, 333 (1978).
- 5 O.H. Lowry, N.R. Rosenbrough, A.L. Farr and R.J. Randall, *J. biol. Chem.* 193, 265 (1951).
- 6 G.A. Robinson, R.W. Bucher and E.W. Sutherland in: *Cyclic AMP*, p.81. Academic Press, New York and London 1971.
- 7 A. Sattin and T.W. Rall, *Molec. Pharmac.* 6, 13 (1970).
- 8 H. Shimizu and Y. Yamamura, *J. Neurochem.* 28, 383 (1977).

## Occurrence of inhibitory histamine $H_2$ -receptors in isolated pulmonary blood vessels of dogs and rats

N. Chand and B.M. Altura<sup>1</sup>

*Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn (New York 11203, USA), 28 January 1980*

**Summary.** Isolated, helically cut strips of pulmonary arteries and veins of dogs, and pulmonary arteries of rats, precontracted with norepinephrine or 5-HT exhibited potent concentration-dependent relaxations to impromidine and dimaprit (histamine  $H_2$ -agonists). The occurrence of inhibitory histamine  $H_2$ -receptors in the pulmonary vasculature could play a modulatory role in hypoxic pulmonary vasoconstriction.

It has been firmly established that histamine acts on at least 2 subtypes of receptors, namely  $H_1$  and  $H_2$ -receptors, which may act in opposite or similar directions in the cardiovascular, respiratory and gastro-intestinal systems<sup>2</sup>. A dual histamine receptor population ( $H_1$ : vasoconstriction;  $H_2$ : vasodilatation) is thought to exist in the intact pulmonary circulation of guinea-pigs, dogs and cats<sup>3</sup>. Although a modulatory role for histamine  $H_2$ -receptors in hypoxic pulmonary vasoconstriction (HPV) has been hypothesized, at least in dogs, cats and rats<sup>4</sup>, the exact anatomical site(s) of these histamine  $H_2$ -receptors in the pulmonary vasculature is not as yet known. In this report, we now demonstrate a potent relaxant effect of impromidine and dimaprit (2 highly specific and potent  $H_2$ -receptor agonists)<sup>5</sup>, on isolated pulmonary blood vessels of rats and dogs.

**Material and methods.** Helically cut strips of pulmonary arteries and veins were prepared after sacrifice<sup>6</sup> from 10 adult mongrel dogs (12–22 kg), of either sex, and 15 male Wistar rats (300–450 g). The tissues were set up isometrically in isolated tissue baths containing Krebs-Ringer bicarbonate solution<sup>6,7</sup>. The tissues were aerated with a 5%  $CO_2$ -95%  $O_2$  mixture, at 37 °C, under a resting load of 2 g for canine pulmonary arterial and venous strips ( $2.3 \times 25$ –30 mm) and 1 g for rat pulmonary arterial strips ( $1.5 \times 20$  mm). After 2 h of equilibration, the tissues were partially contracted with  $ED_{40} \pm 10\%$  concentrations of norepinephrine bitartrate (NE) (50–100 ng/ml) or serotonin creatinine sulfate (5-HT: 10–20 ng/ml) in the case of the canine vessels; for the rat pulmonary artery 0.1–1.0  $\mu$ g/ml of NE and 1–5  $\mu$ g/ml of 5-HT were utilized. Responses to single or cumulative doses of impromidine and dimaprit were then recorded in duplicate. After washing and restoration of baseline tension, the agonists were then tested in the presence of the  $H_2$ -receptor antagonist, metiamide. Grass

FT.03C force transducers and 4-channel Model 5 or 7 polygraphs were utilized, as described previously<sup>7</sup>. Where appropriate, means  $\pm$  SEMs were calculated and compared for statistical significance by Student's t-test.

**Results.** The representative data shown in figures 1 and 2, as well as in the table, clearly demonstrate the inhibitory effects of dimaprit and impromidine on isolated pulmonary arteries and veins of dogs (n=10) and rat pulmonary arteries. In general, impromidine is about 100 times more potent as a relaxant than dimaprit when  $ED_{50}$  concentrations are compared (table). In addition, impromidine produced a greater maximal relaxation than dimaprit (table). Other experiments indicated (8 rats and 5 dogs) that metiamide ( $5 \times 10^{-6}$  M), a specific  $H_2$ -receptor antagonist<sup>2</sup>, failed to alter contractile responses to NE or 5-HT. However, metiamide competitively antagonized relaxant responses of both dimaprit and impromidine (e.g., figure 2; dose ratio=2–5).

**Discussion.** Histamine is contained in relatively large concentrations in the lungs of rats and dogs as well as of other mammals. Histamine has been considered as a mediator, as well as a modulator of HPV<sup>4</sup>, i.e., its exact role in HPV is still not known. Histamine is well-known to induce  $H_1$ -receptor-mediated pulmonary vasoconstriction in several mammalian species so far investigated<sup>2</sup>. However, under the conditions of increased pulmonary vascular tone, such as in HPV, histamine may induce pulmonary vasodilatation. Rat pulmonary arteries are relatively insensitive to the contractile action to histamine<sup>6</sup>, but, as shown here, exhibit potent, dose-dependent relaxations to  $H_2$ -agonists. Thus, there appears to be a preponderance of  $H_2$ -inhibitory receptors in rat pulmonary arteries. On the other hand, canine pulmonary blood vessels possess an abundance of  $H_1$ -receptors, which are susceptible to blockade by

Comparative sensitivity of isolated intrapulmonary arteries of dogs and rats to dimaprit and impromidine (H<sub>2</sub>-agonists)

Agonist	N	Threshold concentration (M) (mean ± SEM)	ED <sub>50</sub> (M) (mean ± SEM)	Maximal relaxant response (mg) (mean ± SEM)
Canine pulmonary arteries				
Dimaprit	7	8.63 ± 2.8 × 10 <sup>-5</sup>	2.91 ± 0.68 × 10 <sup>-4</sup>	390 ± 20
Impromidine	5	1.34 ± 1.1 × 10 <sup>-7</sup> *	2.3 ± 0.57 × 10 <sup>-6</sup> *	650 ± 30*
Rat pulmonary arteries				
Dimaprit	7	9.2 ± 3.7 × 10 <sup>-5</sup>	3.9 ± 1.2 × 10 <sup>-4</sup>	150 ± 10
Impromidine	8	3.7 ± 1.6 × 10 <sup>-7</sup> *	3.8 ± 0.9 × 10 <sup>-6</sup> *	220 ± 15*

\*Significantly different from values obtained with dimaprit (p < 0.01).




Fig. 1. a-c. Typical concentration-response (relaxant) curves of dimaprit and impromidine on norepinephrine-contracted isolated pulmonary artery and vein of dog and pulmonary artery of rat. Agonist concentrations are expressed in  $\mu\text{g/ml}$  of Krebs Ringer solution (added at dots). Norepinephrine was added to induce contraction in the following concentrations: canine pulmonary artery (0.1  $\mu\text{g/ml}$ ), canine pulmonary vein (0.5  $\mu\text{g/ml}$ ), and rat pulmonary artery (0.1  $\mu\text{g/ml}$ ). Vertical bars at left represent tensions in g. Horizontal bars represent time scales.




Fig. 2. Concentration-response (relaxant) curves of H<sub>2</sub>-receptor agonists in the presence and absence of metiamide on isolated rat pulmonary arteries. ○—○, impromidine alone; ●—●, impromidine + metiamide (5 × 10<sup>-6</sup> M); □—□, dimaprit; ■—■, dimaprit + metiamide (5 × 10<sup>-6</sup> M). Figures in parentheses denote numbers of different arteries utilized.

pyrilamine<sup>8</sup>. The enhancement of histamine-induced contractions on canine pulmonary arteries by metiamide (H<sub>2</sub>-antagonist), as well as the marked relaxant responses to impromidine and dimaprit (H<sub>2</sub>-agonists) on both canine pulmonary veins and arteries, demonstrated here, indicate the occurrence of a significant population of H<sub>2</sub>-inhibitory receptors in isolated canine pulmonary blood vessels as well. Others have demonstrated the occurrence of H<sub>2</sub>-inhibitory receptors in isolated pulmonary arteries of puppies<sup>9</sup>, but the present report is the first demonstration of such receptors in pulmonary arteries and veins of adult dogs and rats.

The exposure of the rats to chronic hypoxia results in mast cell hyperplasia in the lungs<sup>10</sup>. Mast cells contain large amounts of histamine, which could be released during hypoxia and may produce a beneficial (pulmonary vasodilator) effect in HPV by activating H<sub>2</sub>-receptors. This tenet is currently being investigated.

In conclusion, the occurrence of inhibitory histamine H<sub>2</sub>-receptor's in mammalian pulmonary arteries and veins could conceivably play a modulatory (protective) role in hypoxic pulmonary vasoconstriction.

- 1 Supported by research grants NHLBI-18002, NHLBI-18015 and DA-02339 from the USPHS. We are grateful to Dr D.D.A. Owen of Smith, Kline & French Ltd, England for the generous supply of dimaprit and impromidine. Requests for reprints should be addressed to B. M. Altura.
- 2 N. Chand and P. Eyre, Agents Actions 5, 277 (1975); B. M. Altura and S. Halevy, in: Handbook of Experimental Pharmacology, vol. 18, part 2; Anti-Histaminics, p. 1. Ed. M. Rocha e Silva. Springer-Verlag, New York 1977; D.A.A. Owen, Gen. Pharmac. 8, 141 (1977); N. Chand, Adv. Pharmac. Chemother., in press (1980).
- 3 A. Tucker, E.K. Weir, J.T. Reeves and R.F. Grover, Am. J. Physiol. 229, 1008 (1975); B. Thompson, G.R. Barer and J.W. Shaw, Clin. exp. Pharmac. Physiol. 3, 399 (1976); E.A. Hoffman, M.L. Munroe, A. Tucker and J.T. Reeves, Resp. Physiol. 29, 255 (1977); G.R. Barer, C.J. Emery, F.H. Mohammed and I.P.F. Mungall, Q. J. exp. Physiol. 631, 157 (1978).
- 4 E.A. Hoffman, M.L. Munroe, A. Tucker and J.T. Reeves, Resp. Physiol. 29, 255 (1977); A.E. Tucker, E.A. Hoffman and E.K. Weir, Chest 71S, 261 (1977); G.R. Barer, C.J. Emery, F.H. Mohammed and I.P.F. Mungall, Q. J. exp. Physiol. 631, 157 (1978).
- 5 M.E. Parsons, D.A.A. Owen, C.R. Ganellin and G.J. Durant, Agents Actions 7, 31 (1977); G.J. Durant, W.A.M. Duncan, C.R. Ganellin, M.E. Parsons, R.C. Blakemore and A.C. Rasmussen, Nature 276, 403 (1978).
- 6 N. Chand and B. M. Altura, J. appl. Physiol., in press (1980).
- 7 B. M. Altura and B. T. Altura, Am. J. Physiol. 219, 1698 (1970).
- 8 N. Chand and B. M. Altura, Fedn Proc., in press (1980).
- 9 J.H. Newman, J.F. Souhrada, J.T. Reeves, C.M. Arroyave and R.F. Grover, Am. J. Physiol. 237, H76 (1979).
- 10 J.M. Kay, J.C. Waymire and R.F. Grover, Am. J. Physiol. 226, 178 (1974).